Skip to content

Study · Randomized controlled trial · 2021

4 results

The Differential and Combined Action of Insulin Glargine and Lixisenatide on the Fasting and Postprandial Components of Glucose Control.

Gautier T, Umpierrez G, Renard E, Kovatchev B

Journal of diabetes science and technology6 Dec 2019Cited by 8 (Europe PMC)

PMID31810389 (opens in a new tab)PMCIDPMC8256059 (opens in a new tab)DOI10.1177/1932296819891170 (opens in a new tab)PepBankPUB-31810389
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with diabetes, adding lixisenatide to insulin glargine reduced prandial mean plasma glucose by 9.7 mg/dL (P < .01).

    In plain wordsIn adults with diabetes, adding lixisenatide to insulin glargine reduced glucose around meals.

    Peptide
    Lixisenatide
    Outcome
    DecreasePrandial mean plasma glucose
    Study

    n: not reported in source

    Comparator
    Insulin glargine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · injection · 30 weeksAs given in this study (human).

    Measurements

    Reduction in prandial mean plasma glucose
    9.7 mg/dL
    lixisenatide added to iGlar

    Source sentences

    Summary
    Lixisenatide, when added to iGlar, reduced PMPG by 9.7 mg/dL (P < .01), AUC by 96.3 mg∙h/dL (P < .01), and PHBGI by 2.4 (P < .01), primarily due to attenuation of PPG and without significant change in mean FPG.
    1 context sentence
    Summary · context
    This post hoc study analyzes data from the Lixilan-O trial, where 1170 subjects with type 2 diabetes were randomly assigned to 30 weeks of once daily injections of lixisenatide, iGlar, and iGlarLixi (1:2:2).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with diabetes, adding lixisenatide to insulin glargine reduced glucose AUC by 96.3 mg∙h/dL (P < .01).

    In plain wordsIn adults with diabetes, adding lixisenatide to insulin glargine reduced overall glucose exposure.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGlycemic exposure
    Study

    n: not reported in source

    Comparator
    Insulin glargine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · injection · 30 weeksAs given in this study (human).

    Measurements

    Reduction in glucose AUC
    96.3 mg∙h/dL
    lixisenatide added to iGlar

    Source sentences

    Summary
    Lixisenatide, when added to iGlar, reduced PMPG by 9.7 mg/dL (P < .01), AUC by 96.3 mg∙h/dL (P < .01), and PHBGI by 2.4 (P < .01), primarily due to attenuation of PPG and without significant change in mean FPG.
    1 context sentence
    Summary · context
    This post hoc study analyzes data from the Lixilan-O trial, where 1170 subjects with type 2 diabetes were randomly assigned to 30 weeks of once daily injections of lixisenatide, iGlar, and iGlarLixi (1:2:2).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with diabetes, adding lixisenatide to insulin glargine reduced the prandial high blood glucose index by 2.4 (P < .01).

    In plain wordsIn adults with diabetes, adding lixisenatide to insulin glargine reduced the index of high glucose around meals.

    Peptide
    Lixisenatide
    Outcome
    DecreasePrandial high blood glucose index
    Study

    n: not reported in source

    Comparator
    Insulin glargine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · injection · 30 weeksAs given in this study (human).

    Measurements

    Reduction in prandial high blood glucose index
    2.4 not stated
    lixisenatide added to iGlar

    Source sentences

    Summary
    Lixisenatide, when added to iGlar, reduced PMPG by 9.7 mg/dL (P < .01), AUC by 96.3 mg∙h/dL (P < .01), and PHBGI by 2.4 (P < .01), primarily due to attenuation of PPG and without significant change in mean FPG.
    1 context sentence
    Summary · context
    This post hoc study analyzes data from the Lixilan-O trial, where 1170 subjects with type 2 diabetes were randomly assigned to 30 weeks of once daily injections of lixisenatide, iGlar, and iGlarLixi (1:2:2).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with diabetes, adding lixisenatide to insulin glargine did not significantly change mean fasting plasma glucose.

    In plain wordsIn adults with diabetes, adding lixisenatide to insulin glargine did not significantly change fasting glucose.

    Peptide
    Lixisenatide
    Outcome
    No significant changeMean fasting plasma glucose
    Study

    n: not reported in source

    Comparator
    Insulin glargine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · injection · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    Lixisenatide, when added to iGlar, reduced PMPG by 9.7 mg/dL (P < .01), AUC by 96.3 mg∙h/dL (P < .01), and PHBGI by 2.4 (P < .01), primarily due to attenuation of PPG and without significant change in mean FPG.
    1 context sentence
    Summary · context
    This post hoc study analyzes data from the Lixilan-O trial, where 1170 subjects with type 2 diabetes were randomly assigned to 30 weeks of once daily injections of lixisenatide, iGlar, and iGlarLixi (1:2:2).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.